

## **Jarlath Keating Joins as President of Solvias Group USA to Drive Growth and Innovation in Advanced Analytical Services**

Industry veteran joins Solvias to lead U.S. expansion and strengthen delivery of advanced analytical solutions for biopharma clients.

*Kaiseraugst, Switzerland - August 4<sup>th</sup>, 2025* — Solvias, a global provider of chemistry, manufacturing, and controls (CMC) analytical services, is pleased to announce the appointment of Jarlath Keating as President Solvias Group USA. In this role, Mr. Keating will provide strategic leadership and operational oversight to accelerate Solvias' growth trajectory in North America and further strengthen its presence in the US market.

With nearly 30 years of experience in the biopharmaceutical and biotechnology sectors, Mr. Keating brings a robust track record of building high-performing teams, fostering customer-focused innovation, and driving commercial success. His leadership spans senior executive roles at Phosphorex, LLC, Advanced Bioscience Laboratories, and BioReliance, where he consistently delivered strong revenue growth and led international commercial operations across complex, fast-evolving markets.

"We are thrilled to welcome Jarlath Keating to the Solvias leadership team," said Archie Cullen, CEO of Solvias. "As we scale our U.S. operations to meet the increasing demand for advanced analytical services, Jarlath's industry expertise and leadership will be instrumental in guiding our next phase of sustainable growth and operational excellence."

Solvias has made substantial investments in its U.S. capabilities, including the expansion of its Research Triangle Park (RTP), North Carolina facility and the recent achievement of cGMP readiness. These advancements position Solvias to support biopharmaceutical customers from early-stage development through commercial release with trusted, compliant, and high-quality analytical services.

"I'm honored to join Solvias at such an exciting and pivotal moment," said Jarlath Keating. "The company's global reputation for scientific excellence and its commitment to customer success are deeply aligned with my own values. I look forward to partnering with our teams across the U.S. and globally to help clients bring life-changing therapies to patients."

Mr. Keating holds a degree in Process Biotechnology from Teesside University in the United Kingdom and has completed executive education programs at Harvard, Stanford, and Georgetown business schools.

---

#### About Solvias

Solvias has 25 years of experience as a provider of chemistry, manufacturing, and controls (CMC) analytics to the global Pharmaceutical and Biotechnology Industry. Its expert team combines decades of experience with regulatory expertise across small molecules, biologics, and cell and gene therapies. Solvias offers end-to-end solutions from raw material testing to drug product release and API development for small molecules. Headquartered near Basel, Switzerland, Solvias operates six global Centers of Excellence, all adhering to the highest ISO, cGMP, GLP, and FDA standards. For more information, visit [solvias.com](http://solvias.com).

#### Media contact

Katy McGirr, Director of Global Marketing

[Katy.mcgirr@solvias.com](mailto:Katy.mcgirr@solvias.com)

+1 617 513 8287

# # #